Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16579321 | 0.84 | MEN1 (0.50) | MEN1BLMKMT2ATACR1 | |
| Hydrochloric Acid SCHEMBL20959290 | 0.81 | MEN1 (0.45) | MEN1BLMKMT2AHTTALDH1A1 | |
| Hydrochloric Acid SCHEMBL20959291 | 0.81 | MEN1 (0.45) | MEN1BLMKMT2AHTTALDH1A1 | |
| SCHEMBL8531744 | 0.77 | TAAR1 (0.40) | TACR1HTR2CHTR2BHCRTR2 | |
| SCHEMBL8531739 | 0.77 | TAAR1 (0.40) | TACR1HTR2CHTR2BHCRTR2 | |
| SCHEMBL8531734 | 0.77 | TAAR1 (0.40) | TACR1HTR2CHTR2BHCRTR2 | |
| SCHEMBL2567672 | 0.75 | RXFP1 (0.44) | MEN1KMT2ARIPK1HTTALDH1A1 | |
| SCHEMBL12160774 | 0.75 | RXFP1 (0.44) | MEN1KMT2ARIPK1HTTALDH1A1 | |
| SCHEMBL29726766 | 0.75 | RXFP1 (0.44) | MEN1KMT2ARIPK1HTTALDH1A1 | |
| SCHEMBL20426001 | 0.75 | RXFP1 (0.44) | MEN1KMT2ARIPK1HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230102258-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2023-03-30 | — | — | US | disclosed |
| EP-4015504-A1 | C5AR ANTAGONISTS | ChemoCentryx, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| EP-3508477-B1 | C5AR ANTAGONISTS | CHEMOCENTRYX INC (US) | 2021-11-10 | — | — | EP | disclosed |
| US-10660897-B2 | C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| EP-3508477-A1 | C5AR ANTAGONISTS | ChemoCentryx, Inc. (US) | 2019-07-10 | — | — | EP | disclosed |
| EP-3078658-B1 | C5AR ANTAGONISTS | CHEMOCENTRYX INC (US) | 2019-04-10 | — | — | EP | disclosed |
| US-10035768-B2 | C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20180179160-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2018-06-28 | — | — | US | disclosed |
| EP-2585064-B1 | C5AR ANTAGONISTS | CHEMOCENTRYX INC (US) | 2017-05-03 | — | — | EP | disclosed |
| US-20170114017-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2017-04-27 | — | — | US | disclosed |
| US-20130172347-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2013-07-04 | — | — | US | disclosed |
| US-8445515-B2 | C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| EP-2585064-A1 | C5AR ANTAGONISTS | ChemoCentryx, Inc. (US) | 2013-05-01 | — | — | EP | disclosed |
| CN-103068385-A | C5ar antagonists | CHEMOCENTRYX INC | 2013-04-24 | — | — | CN | disclosed |
| WO-2011163640-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2011-12-29 | — | — | WO | disclosed |
| CN-102264227-A | C5ar antagonists | — | 2011-11-30 | — | — | CN | disclosed |
| EP-2381778-A1 | C5AR ANTAGONISTS | ChemoCentryx, Inc. (US) | 2011-11-02 | — | — | EP | disclosed |
| US-20100311753-A1 | C5aR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| WO-2010075257-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20100160320-A1 | C5aR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160320-A1 | C5aR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | MEN1 2647/4885BLM 4285/4885KMT2A 4442/4885 |
| US-10660897-B2 | C5aR antagonists | C5AR1, C5AR2, C3AR1 | MEN1 2647/4885BLM 4285/4885KMT2A 4442/4885 |
| US-20170114017-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | MEN1 2647/4885BLM 4285/4885KMT2A 4442/4885 |
| US-20180179160-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | MEN1 2647/4885BLM 4285/4885KMT2A 4442/4885 |
| US-10035768-B2 | C5aR antagonists | C5AR1, C5AR2, C3AR1 | MEN1 2647/4885BLM 4285/4885KMT2A 4442/4885 |
| US-20230102258-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | MEN1 2647/4885BLM 4285/4885KMT2A 4442/4885 |
| US-20100311753-A1 | C5aR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | MEN1 2647/4885BLM 4285/4885KMT2A 4442/4885 |
| US-20130172347-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | MEN1 2647/4885BLM 4285/4885KMT2A 4442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.